LEXINGTON, Mass.--(BUSINESS WIRE)--Xenetic Biosciences, Inc. (OTCQB:XBIO) , a biopharmaceutical company developing next-generation biologic drugs and novel orphan oncology therapeutics, today announced that it has appointed Jeffrey F. Eisenberg to the Company’s Board of Directors.

Mr. Eisenberg is a life sciences executive with over 20 years of operational experience and a successful track record in value creation in both private and public companies. Over the course of his career, he has led all crucial areas of R&D, operations, manufacturing/quality, business development, strategic partnering, product development, commercialization, and talent management.

Commenting on the appointment, Scott Macguire, CEO of Xenetic Biosciences, stated, “We are very pleased to welcome Jeff to Xenetic’s Board of Directors. I have no doubt he will bring a valuable perspective to the Company on the corporate, operational, clinical and commercialization fronts during this important growth phase for Xenetic. His broad skill set complements our current board, and we fully expect to leverage his proven business acumen and solid industry experience.”

Prior to joining the Xenetic Board, Mr. Eisenberg served at Noven Pharmaceuticals, Inc. (“Noven”) for over a decade beginning as Vice President, General Counsel and Corporate Secretary and departing as the President and CEO and a member of the Board of Directors. As CEO, Mr. Eisenberg achieved several notable accomplishments including managing the integration of Noven and Hisamitsu following the acquisition of Noven in 2009, increasing the cash position from $78 million in the year of the acquisition to over $240 million at year end 2015 through organic growth without incurring debt, and achieving FDA approval for the first non-hormonal product to treat menopausal vasomotor symptoms. Mr. Eisenberg also served as Senior Vice President of Strategic Alliances, Interim President and CEO, and Executive Vice President while serving at Noven. Currently, Mr. Eisenberg serves as a member of the Board of Directors of Mabvax Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative vaccine and monoclonal antibody-based therapeutics for the diagnosis and treatment of cancer.

Jeffrey Eisenberg commented, “I am thrilled to be joining the team during this pivotal time for Xenetic. I believe Xenetic is currently taking important steps necessary to propel the Company towards its next phase of growth and believe it is poised to unlock the tremendous potential that exists within its deep pipeline.”

Mr. Eisenberg graduated Magna cum Laude from Wharton School, University of Pennsylvania with his Bachelor of Science degree in Economics and received his Doctor of Law degree from Columbia University Law School in New York.

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics. Xenetic's proprietary drug technology platforms include PolyXen®, designed to develop next generation biologic drugs by extending the efficacy, safety and half-life of biologic drugs.